These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

887 related items for PubMed ID: 22257911

  • 1. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis.
    Schafer P.
    Biochem Pharmacol; 2012 Jun 15; 83(12):1583-90. PubMed ID: 22257911
    [Abstract] [Full Text] [Related]

  • 2. Apremilast in the treatment of psoriasis and psoriatic arthritis.
    Gooderham M, Papp K.
    Skin Therapy Lett; 2015 Jun 15; 20(5):1-6. PubMed ID: 26382906
    [Abstract] [Full Text] [Related]

  • 3. Selective Phosphodiesterase Inhibitors for Psoriasis: Focus on Apremilast.
    Gooderham M, Papp K.
    BioDrugs; 2015 Oct 15; 29(5):327-39. PubMed ID: 26481941
    [Abstract] [Full Text] [Related]

  • 4. Apremilast for the treatment of psoriatic arthritis.
    Souto A, Gómez-Reino JJ.
    Expert Rev Clin Immunol; 2015 Oct 15; 11(12):1281-90. PubMed ID: 26503917
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Apremilast in psoriatic arthritis.
    Schett G.
    Clin Exp Rheumatol; 2015 Oct 15; 33(5 Suppl 93):S98-100. PubMed ID: 26472278
    [Abstract] [Full Text] [Related]

  • 8. Apremilast: A Review in Psoriasis and Psoriatic Arthritis.
    Keating GM.
    Drugs; 2017 Mar 15; 77(4):459-472. PubMed ID: 28213862
    [Abstract] [Full Text] [Related]

  • 9. New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilast.
    Palfreeman AC, McNamee KE, McCann FE.
    Drug Des Devel Ther; 2013 Mar 15; 7():201-10. PubMed ID: 23569359
    [Abstract] [Full Text] [Related]

  • 10. Pharmacodynamic assessment of apremilast for the treatment of moderate-to-severe plaque psoriasis.
    Bianchi L, Del Duca E, Romanelli M, Saraceno R, Chimenti S, Chiricozzi A.
    Expert Opin Drug Metab Toxicol; 2016 Sep 15; 12(9):1121-8. PubMed ID: 27376729
    [Abstract] [Full Text] [Related]

  • 11. Apremilast: A Novel Oral Treatment for Psoriasis and Psoriatic Arthritis.
    Torres T, Puig L.
    Am J Clin Dermatol; 2018 Feb 15; 19(1):23-32. PubMed ID: 28597182
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The phosphodiesterase 4 inhibitor apremilast inhibits Th1 but promotes Th17 responses induced by 6-sulfo LacNAc (slan) dendritic cells.
    Oehrl S, Prakash H, Ebling A, Trenkler N, Wölbing P, Kunze A, Döbel T, Schmitz M, Enk A, Schäkel K.
    J Dermatol Sci; 2017 Aug 15; 87(2):110-115. PubMed ID: 28499587
    [Abstract] [Full Text] [Related]

  • 14. Inhibition of Phosphodiesterase-4 in Psoriatic Arthritis and Inflammatory Bowel Diseases.
    Picchianti-Diamanti A, Spinelli FR, Rosado MM, Conti F, Laganà B.
    Int J Mol Sci; 2021 Mar 05; 22(5):. PubMed ID: 33807944
    [Abstract] [Full Text] [Related]

  • 15. Phosphodiesterase 4 in inflammatory diseases: Effects of apremilast in psoriatic blood and in dermal myofibroblasts through the PDE4/CD271 complex.
    Schafer PH, Truzzi F, Parton A, Wu L, Kosek J, Zhang LH, Horan G, Saltari A, Quadri M, Lotti R, Marconi A, Pincelli C.
    Cell Signal; 2016 Jul 05; 28(7):753-63. PubMed ID: 26806620
    [Abstract] [Full Text] [Related]

  • 16. PDE4 Inhibition and Inflammatory Bowel Disease: A Novel Therapeutic Avenue.
    Spadaccini M, D'Alessio S, Peyrin-Biroulet L, Danese S.
    Int J Mol Sci; 2017 Jun 15; 18(6):. PubMed ID: 28617319
    [Abstract] [Full Text] [Related]

  • 17. Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity.
    Schafer PH, Parton A, Capone L, Cedzik D, Brady H, Evans JF, Man HW, Muller GW, Stirling DI, Chopra R.
    Cell Signal; 2014 Sep 15; 26(9):2016-29. PubMed ID: 24882690
    [Abstract] [Full Text] [Related]

  • 18. Phosphodiesterase 4 Inhibitors in Immune-mediated Diseases: Mode of Action, Clinical Applications, Current and Future Perspectives.
    Sakkas LI, Mavropoulos A, Bogdanos DP.
    Curr Med Chem; 2017 Sep 15; 24(28):3054-3067. PubMed ID: 28554321
    [Abstract] [Full Text] [Related]

  • 19. Apremilast increases IL-10-producing regulatory B cells and decreases proinflammatory T cells and innate cells in psoriatic arthritis and psoriasis.
    Mavropoulos A, Zafiriou E, Simopoulou T, Brotis AG, Liaskos C, Roussaki-Schulze A, Katsiari CG, Bogdanos DP, Sakkas LI.
    Rheumatology (Oxford); 2019 Dec 01; 58(12):2240-2250. PubMed ID: 31209492
    [Abstract] [Full Text] [Related]

  • 20. ▼ Apremilast for psoriasis and psoriatic arthritis.
    Drug Ther Bull; 2015 Sep 01; 53(9):105-8. PubMed ID: 26358317
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 45.